Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients.
Parkinson’s Institute and Clinical Center, which provides comprehensive patient care, while discovering new treatment options to improve the quality of life for all Parkinson’s disease (PD) patients, and Retrotope announced today a collaboration on a new drug therapy to treat patients with Progressive SupraNuclear Palsy (PSP), a type of treatment-resistant PD.
The study is expected to help guide the design of future randomized placebo-controlled trials in PSP. RT001 is the first-in-class of a new drug category called deuterated polyunsaturated fatty acids (D-PUFAs), which are a novel approach to protect against lipid peroxidation damage resulting in cell death that is a hallmark of numerous neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, PSP, Huntington’s disease, ALS and several inherited disorders including Friedreich’s ataxia (FA) and infantile neuroaxonal dystrophy (INAD) in which Retrotope is planning formal clinical trials.
For more details, click here.